GliaPharm SA has completed a CHF 2 million financing. The company is initially focusing on an orphan neurological disease caused by a deficiency in brain metabolism that affects more than 100’000 children around the world from an early age through to adulthood. GliaPharm’s therapeutic approach aims to restore brain energy metabolism in these patients through novel drugs generated with its drug discovery platform GliaXTM. This new approach is promising in offering a treatment to these patients as well as opens the door to broader indications linked to brain metabolism deficiencies, such as dementia or Alzheimer’s disease. For further information, click here.
News
Enterprise